Jazz Pharmaceuticals (JAZZ) Invested Capital (2010 - 2026)

Jazz Pharmaceuticals' Invested Capital history runs 17 years deep, the most recent figure standing at $9.9 billion for Q1 2026.

• In Q1 2026, Invested Capital rose 3.61% year-over-year to $9.9 billion; the TTM figure through Mar 2026 stood at $9.9 billion (up 3.61% YoY), while the FY2025 annual figure was $9.7 billion, down 5.15% from the prior year.
• Invested Capital was $9.9 billion for Q1 2026 at Jazz Pharmaceuticals, up from $9.7 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $10.3 billion in Q3 2024 to a low of $8.5 billion in Q3 2022.
• Historically, Invested Capital has averaged $9.4 billion across 5 years, with a median of $9.4 billion in 2024.
• Biggest YoY gain for Invested Capital was 63.28% in 2022; the steepest drop was 17.08% in 2022.
• A 5-year view of Invested Capital shows it stood at $8.8 billion in 2022, then increased by 7.26% to $9.4 billion in 2023, then climbed by 7.96% to $10.2 billion in 2024, then declined by 5.15% to $9.7 billion in 2025, then climbed by 2.17% to $9.9 billion in 2026.
• The last three Invested Capital figures came in at $9.9 billion (Q1 2026), $9.7 billion (Q4 2025), and $9.3 billion (Q3 2025), per Business Quant data.